stella
beta
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) — Stella
Recruiting
Back to Oral Cavity Squamous Cell Carcinoma trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong
View full record on ClinicalTrials.gov